PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Pharmacological PP2A activation is a druggable approach to overcome MEK inhibitor resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, in two cancer drug response screens, CIP2A depletion was shown to increase the therapeutic response of HeLa and KRAS-mutant lung cancer cells to various cancer therapies (12,13).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [13]
In the citing paper
“The results also support the earlier findings that CIP2A-deficient tumors could constitute a more therapy sensitive subtype (10,12,13).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [13]
In the citing paper
“A series of small molecule PP2A activators, previously termed SMAPs and engineered from phenothiazine parent compounds, drive dephosphorylation of select pathogenic substrates such as c-MYC and ERK with concordant tumor inhibition in an array of in vivo cancer models (Allen-Petersen et al., 2018; Kauko et al., 2018; Sangodkar et al., 2017b).”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Kauko et al., 2018
In the citing paper
“In line with the inability to stabilize AB56αC heterotrimers, these derivative compounds did not induce apoptosis in standard cell culture conditions and had a significantly reduced effect in low serum culture conditions as determined by GI50s (Fig. 4C; Fig S4A) (Kauko et al., 2018; McClinch et al., 2018; Sangodkar et al., 2017a; Tohmé et al., 2019).”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Kauko et al., 2018
In the citing paper
“Importantly, phosphatase activation alone was inferior to the kinase inhibitor treatment alone.”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Kauko et al., 2018
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R., & Hahn, W. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1103 · Cited by 159 · cited 4×
“Whereas PPP2R1A depletion models cells with persistent PP2A inhibition (12), depletion of PP2A inhibitors CIP2A and PME-1 results in cells with tonally high PP2A activity (15, 20).”
InfluentialRetractedControlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Rectangular Confidence Regions for the Means of Multivariate Normal Distributions
Šidák, Z. (1967) · Journal of the American Statistical Association · doi:10.1080/01621459.1967.10482935 · Cited by 2,639 · cited 1×
“When performing multiple comparisons, alpha level was adjusted by Šidák’s (47) or Dunnett’s correction, or FDR was controlled by the BenjaminiHochberg procedure (48).”
MethodRectangular Confidence Regions for the Means of Multivariate Normal Distributions
Šidák, Z. (1967) · Journal of the American Statistical Association · doi:10.2307/2283989 · Cited by 1,455
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Self-citationEnumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., & Weinberg, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2111-2123.2002 · Cited by 612
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins
Ramirez, R. D., Sheridan, S., Girard, L., Sato, M., Kim, Y., Pollack, J., Peyton, M., Zou, Y., Kurie, J. M., DiMaio, J. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-3703 · Cited by 607
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P., Tai, Y.-T., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 585 · cited 1×
“The qualitative difference between cytostatic and cytotoxic response is thought to be important with regard to potential development of therapy resistance and regrowth of the tumor (44).”
BackgroundSpecies- and cell type-specific requirements for cellular transformation
Rangarajan, A., Hong, S. J., Gifford, A., & Weinberg, R. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.009 · Cited by 555 · cited 2×
“In full accordance with a requirement of PP2A inhibition for cellular transformation by activated RAS (6, 7), PP2A inhibition promotes malignant growth of various cell types with RAS activating mutations (15, 17).”
BackgroundPeterson, R. T., Desai, B. N., Hardwick, J. S., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4438 · Cited by 486 · cited 8×
“In cultured cells, PP2A is well known to regulate phosphorylation of AKT (41), several mTOR targets including p70 S6K (42), as well as MYC (32, 39).”
BackgroundInfluentialFarrell, A. S., & Sears, R. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014365 · Cited by 468
Protein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
NetworKIN: a resource for exploring cellular phosphorylation networks
Linding, R., Jensen, L. J., Pasculescu, A., Olhovsky, M., Colwill, K., Bork, P., Yaffe, M. B., & Pawson, T. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm902 · Cited by 393
(2013) · doi:10.1158/2159-8290.cd-13-0350 · Cited by 393 · cited 2×
“The subsequent analyses were carried out as described previously (22).”
MethodSelf-citationYadav, B., Pemovska, T., Szwajda, A., Kulesskiy, E., Kontro, M., Karjalainen, R., Majumder, M. M., Malani, D., Murumägi, A., Knowles, J., et al. (2014) · Scientific Reports · doi:10.1038/srep05193 · Cited by 359 · cited 9×
“DSS (28) was calculated by comparing the response of each siRNA-depleted sample to the average of control samples.”
MethodInfluentialSelf-citationHayes, T. K., Neel, N. F., Hu, C., Gautam, P., Chenard, M., Long, B., Aziz, M., Kassner, M., Bryant, K. L., Pierobon, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.11.011 · Cited by 264 · cited 2×
“S1B) (24, 32, 33) in senescence evasion in KRAS-mutant cells (34).”
BackgroundSelf-citationPhenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia
Gutierrez, A., Pan, L., Groen, R. W. J., Baleydier, F., Kentsis, A., Marineau, J., Grebliunaite, R., Kozakewich, E., Reed, C., Pflumio, F., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65093 · Cited by 220 · cited 1×
“Both tricyclic phenothiazines and the SMAPs directly bind to PPP2R1A (11, 36, 37), and either mutation of the putative SMAP target-binding site on PPP2R1A or overexpression of viral PIP SV40 small t antigen abrogates the anticancer activities of SMAPs (11).”
BackgroundActivation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89548 · Cited by 196 · cited 7×
“We recently demonstrated that the capacity of DT-061 to inhibit H358 xenograft growth was dependent on drug binding to PPP2R1A (11).”
BackgroundMethodInfluentialSelf-citationO’Connor, C. M., Perl, A., Leonard, D., Sangodkar, J., & Narla, G. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.008 · Cited by 190 · cited 2×
“Finally, our screen conducted with 230 kinase inhibitors in PP2A-modulated cells provides a resource for further identification of combination therapy strategies, in particular with pharmacological PP2A modulators such as SMAPs (37).”
BackgroundSelf-citationTargeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Janghorban, M., Farrell, A. S., Allen-Petersen, B. L., Pelz, C., Daniel, C. J., Oddo, J., Langer, E. M., Christensen, D. J., & Sears, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317630111 · Cited by 186
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185
Self-citationCIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis
Dong, Q., Wang, Y., Dong, X.-J., Li, Z., Tang, Z., Cui, Q., & Wang, E. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1313-8 · Cited by 155 · cited 1×
“In lung cancers, PP2A activity is also frequently dampened by overexpression of PP2A inhibitor proteins (PIPs) such as CIP2A (19) or SET (17).”
BackgroundLaine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0292 · Cited by 130
Self-citationKalev, P., Simicek, M., Vazquez, I., Munck, S., Chen, L., Soin, T., Danda, N., Chen, W., & Sablina, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1667 · Cited by 127 · cited 1×
“Because inhibition of PPP2R5 (B56) PP2A complexes by CIP2A overexpression (26) or decreased expression of the PPP2R2 (B55) family subunits (35) is a potential mechanism of PP2A inhibition in human lung cancer cells, we further tested the contributions of both of these PP2A subunit families to trametinib sensitivity.”
Haesen, D., Abbasi Asbagh, L., Derua, R., Hubert, A., Schrauwen, S., Hoorne, Y., Amant, F., Waelkens, E., Sablina, A., & Janssens, V. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3342 · Cited by 124 · cited 3×
“This was based on previously published evidence of both AKT and mTOR as PP2A target pathways (15, 18), including association of PP2A inhibition with mTOR/S6 activation in human salivary gland tumors (30).”
BackgroundMethodResultNon-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111 · cited 1×
“Serine/threonine phosphatase PP2A (protein phosphatase 2A) is a critical human tumor suppressor (4, 5), inhibition of which is a prerequisite for malignant transformation of many types of normal human cells (5–7) and promotes in vivo tumorigenesis (8–14).”
BackgroundSelf-citationProtein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner
Andrabi, S., Gjoerup, O. V., Kean, J. A., Roberts, T. M., & Schaffhausen, B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706696104 · Cited by 104
Ruediger, R., Ruiz, J., & Walter, G. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05744-11 · Cited by 98 · cited 1×
“Notably, in two independent in vivo lung cancer models, PPP2R1A mutation either increased tumor burden or decreased survival of KRAS-mutant mice (8, 10).”
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
Mandal, R., Becker, S., & Strebhardt, K. (2015) · Oncogene · doi:10.1038/onc.2015.329 · Cited by 97
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201642788 · Cited by 95
Self-citationTargeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors
Pitts, T. M., Davis, S. L., Eckhardt, S. G., & Bradshaw‐Pierce, E. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.010 · Cited by 94 · cited 1×
“1E) may be explained both by the nonoverlapping PP2A targets regulated by PME-1 and CIP2A (23) and by nuclear colocalization of PME-1 (29, 30) and AURK targets (31), whereas CIP2A is mostly cytoplasmic (30, 32).”
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
Tibau, A., Moltó, C., Ocaña, A., Templeton, A. J., del Carpio, L. P., Paggio, J. C. D., Barnadas, A., Booth, C. M., & Amir, E. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx232 · Cited by 92
Niemelä, M., Kauko, O., Sihto, H., Mpindi, J.-P., Nicorici, D., Pernilä, P., Kallioniemi, O.-P., Joensuu, H., Hautaniemi, S., & Westermarck, J. (2012) · Oncogene · doi:10.1038/onc.2011.599 · Cited by 79
Self-citationZhou, X., Updegraff, B. L., Guo, Y., Peyton, M., Girard, L., Larsen, J. E., Xie, X.-J., Zhou, Y., Hwang, T. H., Xie, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1267-t · Cited by 78 · cited 6×
“The third PIP, SET, which has the most prominent effects on PP2A activity based on our recent phosphoproteome screen in HeLa cells (23), was excluded from the analysis due to almost complete block of proliferation of A549 cells upon SET siRNA transfection (fig.”
BackgroundInfluentialNaetar, N., Soundarapandian, V., Litovchick, L., Goguen, K. L., Sablina, A. A., Bowman-Colin, C., Sicinski, P., Hahn, W. C., DeCaprio, J. A., & Livingston, D. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.023 · Cited by 67
Kauko, O., Laajala, T. D., Jumppanen, M., Hintsanen, P., Suni, V., Haapaniemi, P., Corthals, G., Aittokallio, T., Westermarck, J., & Imanishi, S. Y. (2015) · Scientific Reports · doi:10.1038/srep13099 · Cited by 61
Self-citationRegulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1
Kaur, A., & Westermarck, J. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160161 · Cited by 55 · cited 1×
“However, because CIP2A and PME-1 do not share structural features and the mechanisms by which they inhibit PP2A activity are vastly different (25, 26), the presumption was that their impacts on kinase inhibitor sensitivity might differ at least to some extent.”
BackgroundSelf-citationMolecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance
Smith, M. P., & Wellbrock, C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0954 · Cited by 51 · cited 3×
“2 of 12 in reactivation of extracellular signal–regulated kinase (ERK) or activation of AKT/mammalian target of rapamycin (mTOR) signaling (2, 21).”
InfluentialLoss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo
Lambrecht, C., Libbrecht, L., Sagaert, X., Pauwels, P., Hoorne, Y., Crowther, J., Louis, J. V., Sents, W., Sablina, A., & Janssens, V (2018) · Oncogene · doi:10.1038/onc.2017.350 · Cited by 50
PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells
Kaur, A., Denisova, O. V., Qiao, X., Jumppanen, M., Peuhu, E., Ahmed, S. U., Raheem, O., Haapasalo, H., Eriksson, J., Chalmers, A. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1134 · Cited by 47 · cited 3×
“Whereas PPP2R1A depletion models cells with persistent PP2A inhibition (12), depletion of PP2A inhibitors CIP2A and PME-1 results in cells with tonally high PP2A activity (15, 20).”
BackgroundSelf-citationPP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer Development
Sents, W., Meeusen, B., Kalev, P., Radaelli, E., Sagaert, X., Miermans, E., Haesen, D., Lambrecht, C., Dewerchin, M., Carmeliet, P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2911 · Cited by 42 · cited 2×
“In addition, deletions and loss-of-function mutations of PP2A subunits have been reported in patients with lung and other cancers (5, 13).”
BackgroundSelf-citationLucas, C. M., Harris, R. J., Holcroft, A. K., Scott, L. J., Carmell, N., McDonald, E., Polydoros, F., & Clark, R. E. (2015) · Leukemia · doi:10.1038/leu.2015.71 · Cited by 37 · cited 1×
“For example, recent evidence in chronic myeloid leukemia has shown that patients with high expression of CIP2A responded only to secondgeneration tyrosine kinase inhibitors (43).”
BackgroundWalter, G., & Ruediger, R. (2012) · Cell Cycle · doi:10.4161/cc.11.3.19057 · Cited by 37 · cited 3×
“The PPP2R1A E64D mutation found in NCI-H460 cells contributes to RAS-driven lung cancer progression (10).”
BackgroundWiredja, D. D., Ayati, M., Mazhar, S., Sangodkar, J., Maxwell, S., Schlatzer, D., Narla, G., Koyutürk, M., & Chance, M. R. (2017) · PROTEOMICS · doi:10.1002/pmic.201700214 · Cited by 29
Self-citationThe Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review
Ntanasis‐Stathopoulos, I., Fotopoulos, G., Tzanninis, I., & Kotteas, E. A. (2016) · Cancer Investigation · doi:10.1080/07357907.2016.1206117 · Cited by 22
Kaur, A., Elzagheid, A. I., Birkman, E., Avoranta, T., Kytölä, V., Korkeila, E. A., Syrjänen, K. J., Westermarck, J. K., & Sundström, J. T. T. (2015) · Cancer Medicine · doi:10.1002/cam4.541 · Cited by 14
Self-citationRules for PP2A-controlled phosphosignalling and drug responsesPreprint
Kauko, O., Imanishi, S. Y., Kulesskiy, E., Laajala, T. D., Yetukuri, L., Laine, A., Jumppanen, M., Haapaniemi, P., Ruan, L., Yadav, B., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/271841 · Cited by 11
Self-citationRoutila, J., Mäkelä, J., Luukkaa, H., Leivo, I. V. V., Irjala, H., Westermarck, J. K., Mäkitie, A. A., & Ventelä, S. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22312 · Cited by 11
Self-citation
Cited by
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 226
Serine, glycine and one‑carbon metabolism in cancer (Review)
Pan, S., Fan, M., Liu, Z., Li, X., & Wang, H. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5158 · Cited by 227
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
Vervoort, S. J., Welsh, S. A., Devlin, J. R., Barbieri, E., Knight, D. A., Offley, S., Bjelosevic, S., Costacurta, M., Todorovski, I., Kearney, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.022 · Cited by 219
Self-citation
Metadata
- Authors
- Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., Haapaniemi, P., Momeny, M., Varila, T., Ohlmeyer, M., Aittokallio, T., Wennerberg, K., Narla, G., & Westermarck, J.
- Affiliations
- Åbo Akademi University (FI)
- Case Comprehensive Cancer Center (US)
- University of Helsinki (FI)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- O’Connor, Caitlin M.
- Kulesskiy, Evgeny
- Narla, Goutham
- Westermarck, Jukka
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 450
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC8335581
- OpenAlex
- W2884137656
- Semantic Scholar
- 7b4b368bc66efb46734e7ae6188a052e7a61d290
- Cited by
- 149
- References
- 48
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 14 · 2023: 21 · 2022: 22 · 2021: 24 · 2020: 19 · 2019: 20 · 2018: 5
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- NIH Office of the Director (R01 CA181654)
- Sigrid Juséliuksen Säätiö
- Academy of Finland (252572, 294850, 310507, 277293)
- Cancer Society of Finland
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- protein phosphatase 2A, PP2A inhibition, MEK inhibitor resistance, KRAS-mutant lung cancer, Akt/mTOR signaling, selumetinib, kinase inhibitor resistance, serine/threonine phosphatase, combination therapy
- MeSH terms
- Animals, Humans, Lung Neoplasms, Male, Mice, Inbred BALB C, Mice, Nude, Mutation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Cellular Senescence, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Protein Phosphatase 2, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.